{"url_path":"/sec/imrx/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1790340/0001790340-26-000055-index.html","accession_number":"0001790340-26-000055","cik":"0001790340","ticker":"IMRX","issuer_name":"Immuneering Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1790340/0001790340-26-000055-index.html","primary_entity_key":"0001790340","primary_entity_name":"Immuneering Corp"},"word_count":143,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\nOn May 15, 2026, Immuneering Corporation (the “Company”) announced its financial results for the quarter ended March 31, 2026 and provided operational updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).\n\nThe information in this Item 2.02 of this Current Report, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing."}